Johnson & Johnson's Myeloma Approval And What It May Mean For JNJ Stock [Yahoo! Finance]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Yahoo! Finance
Johnson & Johnson (NYSE:JNJ) received FDA approval for DARZALEX FASPRO in combination with D-VRd. The regimen is approved for adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. This decision expands treatment options for a specific group of multiple myeloma patients. For Johnson & Johnson, this approval sits at the center of its pharmaceutical business, which includes a range of oncology therapies. Multiple myeloma remains a complex blood cancer, and drug combinations are an important focus across the sector as companies work to refine standards of care. The DARZALEX FASPRO combination adds another option to the treatment toolkit for clinicians. For investors watching NYSE:JNJ, the news illustrates how additional indications can broaden the reach of an existing medicine. It also provides another concrete data point when assessing how the company is building out its drug portfolio and responding to demand in cancer care
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF SymposiumBusiness Wire
- BofA Lifts PT on Johnson & Johnson (JNJ) to $227 From $221 – Here's Why [Yahoo! Finance]Yahoo! Finance
- Johnson & Johnson's Getting Back to Double-Digit Growth. Has the Stock Become a Bargain Buy? [Yahoo! Finance]Yahoo! Finance
- Alcon's Precision7 Weekly Lenses Test Comfort Claims And Growth Hopes [Yahoo! Finance]Yahoo! Finance
- 5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 1/21/26 - Beat
JNJ
Sec Filings
- 2/6/26 - Form 4
- 2/5/26 - Form 144
- 2/5/26 - Form SCHEDULE
- JNJ's page on the SEC website